ANAVEX LIFE SCIENCES CORP. (AVXL) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
AVXL currently has 85.3M outstanding shares. with moderate dilution risk from 24.2M authorized shares representing 28.3% potential dilution. The company has minimally diluted shareholders by 4.79% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 25, 2025 |
10-K filing | 85.3M shares outstanding |
85M | 24M |
| Aug 12, 2025 |
10-Q filing | 85.4M shares outstanding |
85M | 24M |
| Jul 14, 2025 |
S-3 filing: Anavex Life Sciences Corp. may offer and sell shares of its common stock up to an aggregate amount of $300,000,000. |
85M | 24M |
| May 13, 2025 |
10-Q filing | 85.1M shares outstanding |
85M | 0 |
| Feb 12, 2025 |
10-Q filing | 84.8M shares outstanding |
85M | 0 |
| Dec 23, 2024 |
10-K filing | 83.5M shares outstanding |
83M | 0 |
| Aug 06, 2024 |
10-Q filing | 84.5M shares outstanding |
85M | 0 |
| Jul 29, 2024 |
S-3 filing: Anavex Life Sciences Corp. may offer and sell shares of its common stock up to an aggregate amount of $150,000,000. |
82M | 0 |
| May 09, 2024 |
10-Q filing | 82.5M shares outstanding |
82M | 0 |
| Feb 07, 2024 |
10-Q filing | 82.1M shares outstanding |
82M | 0 |
| Nov 27, 2023 |
10-K filing | 79.8M shares outstanding |
80M | 0 |
| Aug 08, 2023 |
10-Q filing | 82.0M shares outstanding |
82M | 0 |
| May 09, 2023 |
10-Q filing | 80.8M shares outstanding |
81M | 0 |
| Feb 07, 2023 |
10-Q filing | 78.0M shares outstanding |
78M | 0 |
| Nov 28, 2022 |
10-K filing | 78.0M shares outstanding |
78M | 0 |
| Aug 09, 2022 |
10-Q filing | 77.9M shares outstanding |
78M | 0 |
| May 10, 2022 |
10-Q filing | 77.4M shares outstanding |
77M | 0 |
| Feb 09, 2022 |
10-Q filing | 76.2M shares outstanding |
76M | 0 |
| Nov 24, 2021 |
10-K filing | 76.0M shares outstanding |
76M | 0 |
| Aug 12, 2021 |
10-Q filing | 75.7M shares outstanding |
76M | 0 |
| Jun 24, 2021 |
8-K filing: Anavex Life Sciences Corp. entered into a securities purchase agreement with Deep Track Capital to sell 2,380,953 shares of common stock in a registered direct offering for gross proceeds of approximately $50 million at a price of $21.00 per share. ($50.0M proceeds) |
70M | 0 |
| May 13, 2021 |
10-Q filing | 70.0M shares outstanding |
70M | 0 |
| Feb 16, 2021 |
10-Q filing | 69.5M shares outstanding |
69M | 0 |
| Dec 28, 2020 |
10-K filing | 67.0M shares outstanding |
67M | 0 |
| Aug 06, 2020 |
10-Q filing | 60.2M shares outstanding |
60M | 0 |
| May 07, 2020 |
10-Q filing | 58.7M shares outstanding |
59M | 0 |
| Feb 06, 2020 |
10-Q filing | 58.7M shares outstanding |
59M | 0 |